Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's disease

Waragai, Masaaki; Nakai, Michikazu; Wei, Jianshe; Fujita, Masayo; Mizuno, Hideya; Ho, Gilbert; Masliah, Eliezer; Akatsu, Hiroyasu; Yokochi, Fusako; Hashimoto, Makoto

doi:10.1016/j.neulet.2007.08.010

Cited by 96 publications

(64 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No differences were reported in serum DJ-1 levels measured in PD patients and healthy controls in a study performed by Maita et al, 86 whereas other studies performed in CSF or plasma reported higher DJ-1 levels in PD patients than controls. 87,88 Moreover, while upregulation of CSF DJ-1 levels in early stages of PD was more marked compared to levels observed in advanced stages and in controls, plasma DJ-1 levels appeared to be higher in advanced disease. Likewise, these studies revealed similar increases in PD and in neurological diseases with primary synucleinopathy.…”

Section: Genetic Markersmentioning

confidence: 94%

See 1 more Smart Citation

Biomarkers for Evaluation of Clinical Efficacy of Multipotential Neuroprotective Drugs for Alzheimer's and Parkinson's Diseases

et al. 2009

View full text Add to dashboard Cite

Summary: During the last century, the world population has shown a staggering increase in its proportion of elderly members and thus neurodegenerative diseases like Alzheimer's disease (AD) and Parkinson's disease (PD), respectively, are becoming an increasing burden on society. Among the diverse, significant challenges facing clinicians, is the improvement of diagnostic measures to detect early and subtle symptoms, a phase in which prevention efforts might be expected to have their greatest impact and provide a measure of disease progression that can be evaluated during the course of drug treatment. At present, clinical diagnosis of AD and PD is based on a constellation of symptoms and manifestations, although the disease originated several years earlier. Given the multiple etiological nature of AD and PD, it is reasonable to assume that the initial causative pathobiological processes may differ between the affected individuals. Therefore, the availability of biological markers or biomarkers will help not only early disease diagnosis, but also delineate the pathological mechanisms more definitively and reliably than the traditional cognitive and neurological phenotypes. In the current article, we review the literature on biochemical, genetic, and neuroimaging biomarkers and discuss their predictive value as indicative for disease vulnerability to detect individuals at risk for PD and AD, and to determine the clinical efficacy of novel, disease-modifying (neuroprotective) strategies.

show abstract

Section: Genetic Markersmentioning

confidence: 94%

“…Likewise, these studies revealed similar increases in PD and in neurological diseases with primary synucleinopathy. 87,88 How DJ-1 and ␣-synuclein in biological fluids may be of use as BMs in differentiating PD from other neurological disorders remains to be established.…”

Section: Genetic Markersmentioning

confidence: 99%

Biomarkers for Evaluation of Clinical Efficacy of Multipotential Neuroprotective Drugs for Alzheimer's and Parkinson's Diseases

et al. 2009

View full text Add to dashboard Cite

show abstract

“…47) DJ-1 is localized in the cytoplasm, nucleus and mitochondria 26,48) and is secreted into culture medium [49][50][51] or serum, [52][53][54][55][56][57][58][59] cerebrospinal fluid, 53,54,60) saliva 61,62) and nipple fluid. 63) DJ-1 is translocated from the cytoplasm to nucleus upon addition of a mitogen to the culture medium 26) and is translocated to mitochondria after oxidative stress.…”

Section: Tumor Suppressor Mm-1 and Neurodegenerationmentioning

confidence: 99%

Common Mechanisms of Onset of Cancer and Neurodegenerative Diseases

Ariga

2015

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Onset of cancer and neurodegenerative disease occurs by abnormal cell growth and neuronal cell death, respectively, and the number of patients with both diseases has been increasing in parallel with an increase in mean lifetime, especially in developed countries. Although both diseases are sporadic, about 10% of the diseases are genetically inherited, and analyses of such familial forms of gene products have contributed to an understanding of the molecular mechanisms underlying the onset and pathogenesis of these diseases. I have been working on c-myc, a protooncogene, for a long time and identified various c-Myc-binding proteins that play roles in c-Myc-derived tumorigenesis. Among these proteins, some proteins have been found to be also responsible for the onset of neurodegenerative diseases, including Parkinson's disease, retinitis pigmentosa and cerebellar atrophy. In this review, I summarize our findings indicating the common mechanisms of onset between cancer and neurodegenerative diseases, with a focus on genes such as DJ-1 and Myc-Modulator 1 (MM-1) and signaling pathways that contribute to the onset and pathogenesis of cancer and neurodegenerative diseases.

show abstract

“…DJ-1, which is the only chaperone to be included in this study, is a mitochondrial chaperone which has been one of the most studied proteins for its potential use as a PD biomarker. However, results published thus far from measurements of DJ-1 in CSF (Hong et al, 2010) and serum from PD patients (Hong et al, 2010;Shi et al, 2010;Waragai et al, 2007) are somewhat controversial or inconsistent, which could probably be explained by the high DJ-1 protein level present in blood cells (Shi et al, 2010). Currently, it is well established that certain proteins, including members of the Hsp70 family such as Hsp701A and 1B, display perturbed expression levels in the SN of PD brains (Hauser et al, 2005); however, changes in tissue expression levels are in principle not useful for an application as biomarkers.…”

Section: The Hsp70 Machinery Members As Biomarkers Of Pdmentioning

confidence: 99%